Abstract
Background: Heart failure is considered the most prevalent cause of cardiovascular mortality, in addition to decreased quality of life inspite of the availabiity of numerous therapeutic agents and strategies. Sacubitril combined with Valsartan is one of the new modalities that is thought to decrease the mortality rate and hospitalization due to heart failure decompensation.
Objective: This systematic review aims at summarizing the evidence on the novel agent sacubitril combined with valsartan and its outcomes in terms of mortality and recurrent hospitalization in heart failure patients.
Method: We searched Pubmed database thouroughly in the last eighteen years from 2000 to 2018 for trials investigating sacubitril outcomes in heart failure. Both compensated and decompensated heart failure were included.
Result: A total of 82 trials were found. After refining research to include studies published in English and recruted human subjects, 52 papers were found. The trials were further filtered to include only the trials mentioning the follow up duration, baseline Ejection fraction and New York Heart Association (NYHA) classification. Only nine trials were matching to the inclusion criteria.
Conclusion: Sacubitril/valsartan combination appears to be a promising option in patients with heart failure especially those with reduced ejection fraction (<= 40%) in terms of decreasing cardiovascular mortality and reducing hospitalization due to heart failure decompensation. Further trials are still required to test the safety and efficacy.